Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs

Annals of Surgery

Volumn 228, Issue 6, 1998, Pages 763-770

  Van Ijken, Marc G A ^a   De Bruijn, Ernst A ^b   De Boeck, Gert ^c   Ten Hagen, Timo L M ^a   Van Der Sijp, Joost R M ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; MITOMYCIN C; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; BALLOON CATHETER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MIXTURE; DRUG UPTAKE; INOPERABLE CANCER; ISOLATED HYPOXIC HEPATIC PERFUSION; LIVER CARCINOMA; LIVER CIRCULATION; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; SURGICAL TECHNIQUE; SWINE;

ANIMALS; BALLOON DILATATION; CELL HYPOXIA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEASIBILITY STUDIES; LIVER; MELPHALAN; MITOMYCIN; SWINE; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032471947     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199812000-00007     Document Type: Conference Paper

References (49)

1. London WT. Primary hepatocellular carcinoma. Etiology, pathogenesis, and prevention. Hum Pathol 1981; 12:1085-1097.
2. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6:729-738.
3. Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 1984; 54:1461-1465.
4. Sugarbaker PH. In DeVita VT, Hellman S, Rosenberg SA, eds. Principles of cancer treatment. New York: Lippincott-Raven, p. 795.
5. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278-284.
6. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210:127-138.
7. Scheele J, Strangl R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
8. Colins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498-504.
9. Kemeny N, Schneider A. Regional treatment of hepatic metastases and hepatocellular carcinoma. Curr Probl Cancer 1989; 13:197-283.
10. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 471:2986-2989.
11. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 1987; 56:803-808.
12. Eggermont AMM, Schraffordt Koops H, Liénard D. et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665.
13. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg 1996; 224:756-765.
14. Aigner KR, Walther H, Tonn JC, et al. Die isolierte Leberperfusion mit 5-Fluorouracil (5-FU) beim Menschen. Chirurgerie 1982; 53:571-573.
15. Skibba JL, Almagro KA, Condon RE, Petroff RJA. A technique for isolation perfusion of the canine liver with survival. J Surg Res 1983; 34:123-132.
16. Van de Velde CJH, Kothuis BJL, Barenbrug HWM, et al. A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res 1986; 41:593.
17. Borel Rinkes IHM, De Vries MR, Jonker AM, et al. Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 1997; 75:1447-1453.
18. Fraker DL, Alexander HR, Thorn AK. Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 1994; 44:45-50.
19. de Vries MR, Borel Rinkes IHM, Van de Velde CJH, et al. Isolated hepatic perfusion with TNF-α and melphalan: experimental studies in pigs and phase I data from humans. Rec Results Cancer Res 1998; 147:107-119.
20. Kihara T, Nakawa H., Agishi T, et al. Superiority of selective bolus infusion and simultaneous rapid removal of anticancer agents by charcoal hemoperfusion in cancer treatment. Trans Am Soc Artificial Organs 1988; 34:581-584.
21. Aigner KR, Muller H, Walther H, et al. Drug filtration in high-dose regional chemotherapy. In Aigner KR, Patt YZ, Link KH, Kreidler J, eds. Contributions to oncology. Basel: Karger, 1988:261-273.
22. Curley SA, Newman RA, Dougherty TB, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994; 1:389-399.
23. Aigner KR. Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis -rationale and technique. Reg Cancer Treat 1993; 6:3.
24. Aigner KR, Kaevel K. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 1994; 7:6-11.
25. Aigner KR. Pelvic stopflow infusion and hypoxic pelvic perfusion -techniques and pharmacokinetics. Reg Cancer Treat (in press).
26. Thompson JF, Liu M, Watson LD, et al. A percutaneous aortic "stopflow" infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994; 7:202-207.
27. Turk PS, Belliveau JF, Darnowski JW, et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 1993; 128:533-539.
28. Wanebo HJ, Chung MA, Levy AI, et al. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Ann Surg Oncol 1996; 3:295-303.
29. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-6465.
30. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumor cells. Cancer Res 1981; 41:73-81.
31. Engelberts I, Moller A, Schoen GJM, et al. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 1991; 10:69-76.
32. De Boeck G, Van Cauwenberghe K, Eggermont AMM, et al. Determination of melphalan and hydrolysis products in body fluids by GC-MS. J High Res Chromat 1997; 20:697-700.
33. Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990; 531:235-294.
34. De Brauw LM, Marinelli A, van de Velde CJH, et al. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res 1991; 51:1694-1700.
35. Fajardo LF, Kwan HH, Kowalski J, et al. Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 1992; 140:539-544.
36. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin aVb3 in the disruption of the tumor vasculature induced by TNF and IFN-γ Nat. Med. 1998; 4:408-414.
37. Renard N, Nooijen PTGA, Schalkwijk L, et al. vWF release and platelet aggregation in human melanoma after perfusion with TNF-α. J Pathol 1995; 176: 279-287.
38. Marinelli A, van de Velde CJH, Kuppen PJK, et al. A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 1990; 62:891-896.
39. Marinelli A, van Dierendonck JH, van Brakel GM, et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 1991; 64:1069-1075.
40. Aigner KR. Isolated liver perfusion: 5-year results. Reg Cancer Treat 1988; 1:11-20.
41. Häfstrom LR, Holmberg SB, Naredi PL, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994; 3:103-108.
42. Vahrmeijer AL, van der EB MM, van Dierendonck JH, et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin Surg Oncol 1998; 14:262-268.
43. Van Ijken MGA, Wiggers T, van Eijck CHJ, et al. Development of hypoxic pelvic perfusion and hypoxic abdominal perfusion as therapeutic modalities for irresectable tumors: a pharmacokinetic study in pigs [abstract]. Proc Am Ass Cancer Res 1997; 38:597.
44. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumor necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80:995-997.
45. Liénard D, Ewalenko P, Delmotte JJ, et al. High doses of tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
46. Fraker DL, Alexander HR, Andrich M, et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479-489.
47. Renard N, Liénard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rhTNFα). Int J Cancer 1994; 57:656-663.
48. Nooijen PTGA, Manusama ER, Eggermont AMM, et al. Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 1996; 74:1908-1915.
49. Alexander HR, Baartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor-α (TNFα) and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479-89.